Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Sohag University
120 participants
Jan 1, 2025
OBSERVATIONAL
Conditions
Summary
Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokines
Eligibility
Inclusion Criteria4
- ● Aged ≥18 years.
- SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls.
- Patients cooperative and can answer questions.
- Patients who are able and willing to give written informed consent
Exclusion Criteria16
- ● Individuals with other autoimmune diseases.
- Patients receive any hyperuricemia treatment
- Pregnancy
- Malignancy
- Diabetes.
- Hypertension.
- Heart failure.
- Hepatic diseases.
- Chronic renal failure other than lupus nephritis.
- Renal artery stenosis.
- Renal vein thrombosis.
- Intrarenal arteriovenous fistula.
- Obstructive nephropathy.
- Urinary tract obstruction that could affect RI of intra renal arteries.
- Uncooperative patients.
- Patients not able and willing to give written informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
focused on the importance of IL-17 in SLE, and its relation to different disease activity
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07017868